Skip to main content

Table 6 Differences in recommended surveillance imaging between NCCN and ESMO guidelines

From: Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective

 

NCCN, Version 1 2018 [3]

ESMO, 2018 [13]

Frequency

Stage 1: every 6–12 months

Low-grade STS: every 4–6 months in the first 3–5 years, then annually

Stage II/III: every 3–6 months for 2–3 years, then every 6 months for next 2 years, then annually

Intermediate/high-grade STS: Every 3–4 months in the first 2–3 years; then twice a year up to the fifth year and once a year thereafter.

Modality

Primary site: MRI with or without contrast and/or CT with contrast or ultrasound for small, superficial lesions by an experienced ultrasonographer

Primary site: clinical assessment

Chest: CT chest or chest X-ray

Chest: chest X-rays or CT chest at longer intervals